Design Therapeutics Inc
NASDAQ:DSGN

Watchlist Manager
Design Therapeutics Inc Logo
Design Therapeutics Inc
NASDAQ:DSGN
Watchlist
Price: 4.47 USD 1.36% Market Closed
Updated: May 20, 2024

Design Therapeutics Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Design Therapeutics Inc
Cash Equivalents Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Design Therapeutics Inc
NASDAQ:DSGN
Cash Equivalents
$21.2m
CAGR 3-Years
107%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash Equivalents
$18.1B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
8%
Gilead Sciences Inc
NASDAQ:GILD
Cash Equivalents
$4.7B
CAGR 3-Years
5%
CAGR 5-Years
-23%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash Equivalents
$9.7B
CAGR 3-Years
17%
CAGR 5-Years
6%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash Equivalents
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
26%
CAGR 10-Years
36%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash Equivalents
$2.6B
CAGR 3-Years
22%
CAGR 5-Years
9%
CAGR 10-Years
19%

See Also

What is Design Therapeutics Inc's Cash Equivalents?
Cash Equivalents
21.2m USD

Based on the financial report for Dec 31, 2023, Design Therapeutics Inc's Cash Equivalents amounts to 21.2m USD.

What is Design Therapeutics Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
107%

Over the last year, the Cash Equivalents growth was -20%. The average annual Cash Equivalents growth rates for Design Therapeutics Inc have been 107% over the past three years .